India to United States: Furosemide Export Trade Route

The India to United States Furosemide corridor is one of India's established pharmaceutical export routes, with 1,671 shipments documented worth a combined $33.5M USD. The route is dominated by BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED, which alone accounts for roughly 37% of all export value, reflecting the consolidated nature of India's furosemide manufacturing sector.

Across 16 active suppliers, the average shipment value stands at $20.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 82% of all shipments, consistent with furosemide's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 31 days port-to-port. The route has recorded an annual growth rate of 25.7%, placing it at rank #12 among India's top furosemide export destinations globally.

On the import side, key buyers of Indian furosemide in United States include BAXTER HEALTHCARE CORPORATION, RISING PHARMA HOLDINGS, INC., RISING PHARMA HOLDINGS INC and 56 others. BAXTER HEALTHCARE CORPORATION is the single largest importer with 48 shipments valued at $11.5M USD.

India's furosemide exports to United States are driven primarily by a handful of large-scale manufacturers. BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED with 52 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 16 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED, GRAVITI PHARMACEUTICALS PRIVATE LIMITED, PFIZER HEALTHCARE INDIA PRIVATE LIMITED — together account for 80% of total trade value on this route. The average shipment value of $20.0K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as furosemide inj usp 10mg/ml2mlgv ain00218 and furosemide injection usp10mg/ml 10ml gvain00214, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BAXTER HEALTHCARE CORPORATION is the largest importer with 48 shipments worth $11.5M USD — representing 34% of all furosemide imports from India on this route. A total of 59 buyers are active on this corridor.